Tasked with reimagining patient-centric cancer clinical trials, the Bloomberg New Economy International Coalition has identified eliminating patient identification and enrollment barriers as top priorities for accelerating the development of novel cancer treatments, screening, and prevention. The priorities outlined in the April 2022 issue of Nature align with our long-standing call to broaden clinical trial accessibility and, subsequently, data diversity and generalizability by eliminating the obstacles preventing truly representative enrollment.
